Detailansicht
ADME and Translational Pharmacokinetics / Pharmacodynamics of Therapeutic Proteins
eBook - Applications in Drug Discovery and Development
ISBN/EAN: 9781118898802
Umbreit-Nr.: 8757309
Sprache:
Englisch
Umfang: 480 S., 20.86 MB
Format in cm:
Einband:
Keine Angabe
Erschienen am 26.10.2015
Auflage: 1/2015
E-Book
Format: PDF
DRM: Adobe DRM
- Zusatztext
- <p>With an emphasis on the fundamental and practical aspects of ADME for therapeutic proteins, this book helps readers strategize, plan and implement translational research for biologic drugs.</p><p> Details cutting-edge ADME (absorption, distribution, metabolism and excretion) and PKPD (pharmacokinetic / pharmacodynamics) modeling for biologic drugs<br /> Combines theoretical with practical aspects of ADME in biologic drug discovery and development and compares innovator biologics with biosimilar biologics and small molecules with biologics, giving a lessons-learned perspective<br /> Includes case studies about leveraging ADME to improve biologics drug development for monoclonal antibodies, fusion proteins, pegylated proteins, ADCs, bispecifics, and vaccines<br /> Presents regulatory expectations and industry perspectives for developing biologic drugs in USA, EU, and Japan<br /> Provides mechanistic insight into biodistribution and target-driven pharmacokinetics in important sites of action such as tumors and the brain</p>
- Kurztext
- With an emphasis on the fundamental and practical aspects of ADME for therapeutic proteins, this book helps readers strategize, plan and implement translational research for biologic drugs. &bull;&nbsp;Details cutting-edge ADME (absorption, distribution, metabolism and excretion) and PKPD (pharmacokinetic / pharmacodynamics) modeling for biologic drugs&bull;&nbsp;Combines theoretical with practical aspects of ADME in biologic drug discovery and development and compares innovator biologics with biosimilar biologics and small molecules with biologics,&nbsp; giving a lessons-learned perspective &bull;&nbsp;Includes case studies about leveraging ADME to improve biologics drug development for monoclonal antibodies, fusion proteins, pegylated proteins, ADCs, bispecifics, and vaccines&bull;&nbsp;Presents regulatory expectations and industry perspectives for developing biologic drugs in USA, EU, and Japan&bull;&nbsp;Provides mechanistic insight into biodistribution and target-driven pharmacokinetics in important sites of action such as tumors and the brain
- Autorenportrait
- <b>Honghui Zhou</b> is a Senior Director and Janssen Fellow, at Janssen Research& Development, LLC and US head of Pharmacological and Translational Modeling. Board-certified by the American Board of Clinical Pharmacology and a Fellow of American Association of Pharmaceutical Scientists (AAPS) and American College of Clinical Pharmacology (ACCP), he has authored 200 peer-reviewed scientific papers, book chapters, and conference abstracts and co-edited the book<i>Drug-Drug Interactions for Therapeutic Biologics</i> (Wiley, 2013).<br /><br /><b>Frank-Peter Theil</b> heads nonclinical development at UCB Biopharma. Dr. Theil has authored and co-authored 40 research publications, three book chapters and he has given numerous invited presentations at national and international scientific meetings. He is a member of the American Association of Pharmaceutical Scientists (AAPS) and American Society of Clinical Pharmacology and Therapeutics (ASCPT).